B cell receptor signaling: Picky about PI3Ks

Science Signaling

Volumn 3, Issue 134, 2010, Pages

  Limon, Jose J ^a   Fruman, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PRE B CELL RECEPTOR; PROTEIN P100 ALPHA; PROTEIN P100 DELTA; PROTEIN P110; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; B-LYMPHOCYTES; GENES, RAG-1; MICE; MODELS, IMMUNOLOGICAL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

MUS;

EID: 77956626486     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.3134pe25     Document Type: Review

References (25)

1. J. A. Deane, D. A. Fruman, Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu. Rev. Immunol.22, 563-598 (2004).
2. B. Vanhaesebroeck, S. J. Leevers, K. Ahmadi, J. Timms, R. Katso, P. C. Driscoll, R. Woscholski, P. J. Parker, M. D.Waterfield, Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem.70, 535-602 (2001).
3. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, B. Bilanges, The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol.11, 329-341 (2010).
4. K. Okkenhaug, K. Ali, B. Vanhaesebroeck, Antigen receptor signalling: A distinctive role for the p110δ isoform of PI3K. Trends Immunol. 28, 80-87 (2007).
5. F. Ramadani, D. J. Bolland, F. Garcon, J. L. Emery, B. Vanhaesebroeck, A. E. Corcoran, K. Okkenhaug, The PI3K isoforms p110α and p110δ are essential for pre-B cell receptor signaling and B cell development. Sci. Signal. 3, ra60 (2010).
6. L. C. Foukas, M. Claret, W. Pearce, K. Okkenhaug, S. Meek, E. Peskett, S. Sancho, A. J. Smith, D. J. Withers, B. Vanhaesebroeck, Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370 (2006).
7. L. Srinivasan, Y. Sasaki, D. P. Calado, B. Zhang, J. H. Paik, R. A. DePinho, J. L. Kutok, J. F. Kearney, K. L. Otipoby, K. Rajewsky, PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573-586 (2009).
8. K. P. Lam, R. Kühn, K. Rajewsky, In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell90, 1073-1083 (1997).
9. L. Wen, J. Brill-Dashoff, S. A. Shinton, M. Asano, R. R. Hardy, K. Hayakawa, Evidence of marginalzone B cell-positive selection in spleen. Immunity 23, 297-308 (2005).
10. S. Herzog, M. Reth, H. Jumaa, Regulation of Bcell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9, 195-205 (2009).
11. J. G. Monroe, Ligand-independent tonic signaling in B-cell receptor function. Curr. Opin. Immunol. 16, 288-295 (2004).
12. K. Okkenhaug, A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, W. Pearce, S. E. Meek, A. Salpekar, M. D. Waterfield, A. J. Smith, B. Vanhaesebroeck, Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science297, 1031-1034 (2002).
13. A. Bilancio, K. Okkenhaug, M. Camps, J. L. Emery, T. Ruckle, C. Rommel, B. Vanhaesebroeck, Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: Comparative analysis of genetic and pharmacologic interference with p110δ function in B cells. Blood 107, 642-650 (2006).
14. E. Clayton, G. Bardi, S. E. Bell, D. Chantry, C. P. Downes, A. Gray, L. A. Humphries, D. Rawlings, H. Reynolds, E. Vigorito, M. Turner, A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med.196, 753-763 (2002).
15. S. T. Jou, N. Carpino, Y. Takahashi, R. Piekorz, J. R. Chao, N. Carpino, D. Wang, J. N. Ihle, Essential, nonredundant role for the phosphoinositide 3-kinase p110δ signaling by the B-cell receptor complex. Mol. Cell. Biol.22, 8580-8591 (2002).
16. Y. Aiba, M. Kameyama, T. Yamazaki, T. F. Tedder, T. Kurosaki, Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 111, 1497-1503 (2008).
17. Y.Wang, S. R. Brooks, X. Li, A. N. Anzelon, R. C. Rickert, R. H. Carter, The physiologic role of CD19 cytoplasmic tyrosines. Immunity 17, 501-514 (2002).
18. P. Delgado, B. Cubelos, E. Calleja, N. Martínez- Martín, A. Ciprés, I. Mérida, C. Bellas, X. R. Bustelo, B. Alarcón, Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol.10, 880-888 (2009).
19. J. J. Zhao, T. M. Roberts, PI3 kinases in cancer: From oncogene artifact to leading cancer target. Sci. STKE2006, pe52 (2006).
20. R. Marone, V. Cmiljanovic, B. Giese, M. P. Wymann, Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim. Biophys. Acta 1784, 159-185 (2008).
21. R. E. Davis, V. N. Ngo, G. Lenz, P. Tolar, R. M. Young, P. B. Romesser, H. Kohlhammer, L. Lamy, H. Zhao, Y. Yang, W. Xu, A. L. Shaffer, G. Wright, W. Xiao, J. Powell, J. K. Jiang, C. J. Thomas, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, R. D. Gascoyne, J. M. Connors, N. A. Johnson, L. M. Rimsza, E. Campo, E. S. Jaffe, W. H. Wilson, J. Delabie, E. B. Smeland, R. I. Fisher, R. M. Braziel, R. R. Tubbs, J. R. Cook, D. D.Weisenburger, W. C. Chan, S. K. Pierce, L. M. Staudt, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature463, 88-92 (2010).
22. L. C. Foukas, I. M. Berenjeno, A. Gray, A. Khwaja, B. Vanhaesebroeck, Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. U.S.A. 107, 11381-11386 (2010).
23. E. A. Papakonstanti, O. Zwaenepoel, A. Bilancio, E. Burns, G. E. Nock, B. Houseman, K. Shokat, A. J. Ridley, B. Vanhaesebroeck, Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J. Cell Sci.121, 4124-4133 (2008).
24. D. C. Otero, A. N. Anzelon, R. C. Rickert, CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J. Immunol.170, 73-83 (2003).
25. Funding sources: Supported by NIH grant AI085462 (D.A.F.) and a Faculty Mentor Program fellowship from the University of California, Irvine (J.J.L.). Competing interests: D.A.F. is a scientific advisor for Intellikine, a company that is developing PI3K inhibitors.